Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beinaglutide vs CSII in Newly Diagnosed Type 2 Diabetes
NCT03987308Recruiting
- Sponsor
- Beijing Hospital
- Start
- Jul 2019
- Primary completion
- Sep 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial of beinaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Beijing Hospital. Primary endpoint: Proportion of subjects achieving HbA1c <7.0%, no weight increase, and no hypoglycemia at 8 weeks. Started Jul 2019; status: recruiting.
02
Drugs
beinaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03987308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03987308.